Phase II Non-Randomized Two Arm Trial of Induction Chemotherapy With Nab-Paclitaxel and Cisplatin (AP: Arm 1) or Single Agent Nab-paclitaxel (A: Arm 2) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC): "The APA Trial".

Trial Profile

Phase II Non-Randomized Two Arm Trial of Induction Chemotherapy With Nab-Paclitaxel and Cisplatin (AP: Arm 1) or Single Agent Nab-paclitaxel (A: Arm 2) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC): "The APA Trial".

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2017

At a glance

  • Drugs Cisplatin (Primary) ; Paclitaxel (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 13 Apr 2016 Status changed from not yet recruiting to recruiting.
    • 28 Mar 2016 Planned End Date changed from 1 Jul 2028 to 1 Oct 2028 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top